Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain
Listen to this summary
The authors investigate the role of lanthionine synthetase C-like protein 1 (LanCL1) in chronic neuropathic pain, seeking to determine its potential as a therapeutic target. They demonstrate that the novel peptide ligand LAT8881 effectively reverses mechanical allodynia in rodent models of neuropathic pain by modulating LanCL1 activity, highlighting its critical role in neuropathic hypersensitivity. The study suggests that targeting LanCL1 could offer new avenues for treating neuropathic pain.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Pain
View all →More in Anesthesiology
View all →Aug 7, 2026 · Critical care medicine
Telemedicine Critical Care Billing For Hospitalized Medicare Fee-For-Service Beneficiaries, 2018-2024
Aug 7, 2026 · Critical care medicine
Geographic Access to Care and Mortality in Cardiogenic Shock: A Nationwide Cohort Analysis
Aug 7, 2026 · Anesthesiology
Fragility Index of Randomized Clinical Trials in Perioperative Anesthesia: A Methodological Survey of Guideline-Supporting Evidence
Aug 7, 2026 · Anesthesiology
Effect of Pre-operative Intravenous Crystalloid Bolus on Post-Induction Blood Pressure - a randomized blinded intervention trial
Aug 7, 2026 · Critical care medicine
Rethinking Muscle Wasting in Critical Illness: A Systematic Review and Meta-Analysis of Myofiber Size and Protein Turnover
Aug 6, 2026 · Critical care medicine
Targeted Temperature Management at 35°C vs. 37°C for Heatstroke in ICU: A Pilot Randomized Controlled Trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
